Drug Type Small molecule drug |
Synonyms |
Target |
Action agonists, activators |
Mechanism IRE1 agonists(Serine/threonine-protein kinase/endoribonuclease IRE1 agonists), PERK activators(eukaryotic translation initiation factor 2 alpha kinase 3 activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H33ClN2O2 |
InChIKeyDBHCSAFZYROWFD-LPOZWGFCSA-N |
CAS Registry1616292-40-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | China | 18 Mar 2016 |